AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Which Is More Suitable For Aggressive Investors Index Fund Vs Target Date weighs volatility, potential upside, and suitability for growth-focused plans.
28,574 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Three loaded supertankers crossed the Strait of Hormuz this weekend, continuing flows even after Iran asserted a shut...
Investors on Wall Street are pouring capital into Ukraine's drone technology, led by Swarmers, signaling a new phase ...
As Rivian gears up for the upcoming earnings release, two major catalysts could shape the stock's trajectory. This gu...
Investors are shifting away from speculative hydrogen plays toward a blue-chip, high-yield industrial stock. Here’s w...
SpaceX begins trading on Nasdaq, positioning Elon Musk for trillionaire status as investors bet on a bold, multi-plan...
Imagine a beloved sneaker brand reinventing itself with AI and a bold rebrand. This speculative piece explores how su...
NIO delivered a surprising Q4 2025 GAAP profit and outlined a 2026 path to positive non-GAAP earnings, supported by m...
At New Delhi's AI Impact Summit, a staged gesture exposed rivalries among top AI leaders, triggering a rethink of AI ...
Berkshire Hathaway’s surprise Alphabet investment signals a bold, long-term bet from Buffett. Learn the reasoning, ri...
SpaceX is set to go public on NASDAQ this Friday, with analysts predicting a historic IPO. Markets monitor the offeri...
A political shift in the United States is denting confidence in mRNA medicine, with funding drying up and manufacturi...